RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE

Viridian Therapeutics, Inc.\DEVRDN

Market cap
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Collaboration revenue - related party----841320
Research and Development Expense (Excluding Acquired in Process Cost)------2857101160
General and administrative78811111213263595
Total operating expenses11141631414611183136255
Loss from operations-7-11-13-27-33-42-110-80-134-254
Interest and other income--------519
Interest and other expense---0111002
Other income, net---01100417
Net loss-8-11-13-27-33-42-111-79-130-238
Earnings Per Share, Basic--------6.66-4.05-5.31
Earnings Per Share, Diluted--------6.66-4.05-5.31
Change in unrealized loss on investments-----00-0-0-0-
Net loss-8-11-13-27-33-42-111-79-130-238
Total other comprehensive (loss) gain---------01
Change in unrealized (loss) gain on investments---------1
Total other comprehensive (loss) gain---------01
Total comprehensive loss-----33-42-111-80-130-237